Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 _^AM – 8:00 _^PM ET, excluding holidays.

PLUVICTO has been studied in men across different types of PSMA+ metastatic prostate cancer (mPC): mHSPC (also known as mAPMN/S prostate cancer) and mCRPC (also known as mAPMR prostate cancer).^1,2 Whether you are newly diagnosed with mPC or have already been living with it, every treatment matters.³ Now may be the time for something different.

mAPMN/S prostate cancer, metastatic androgen pathway modulation-naïve or -sensitive prostate cancer; mAPMR prostate cancer, metastatic androgen pathway modulation-resistant prostate cancer; mCRPC, metastatic castration-resistant prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer; PET, positron emission tomography; PSMA+, prostate-specific membrane antigen–positive.

Want to see how PLUVICTO could help you too? Answer the following questions to get you to the PLUVICTO results relevant to your type of mPC.

Curious about doctors' takes on PLUVICTO?

Listen in as Dr Mehta and Dr Mehlhaff reflect on how they describe treatment options like PLUVICTO to their patients.*

“Sometimes patients come to me asking about their PSMA status...I am already thinking about ordering a PSMA-PET scan anyway, so it is nice to be on the same wavelength.” — Dr Amit Mehta

*Health care provider experiences are individual and vary. Dr Mehta and Dr Mehlhaff were compensated for their participation in this video.